参考文献/References:
[1] BLOEM B R,OKUN M S,KLEIN C.Parkinson′s disease[J].Lancet,2021,397(10291):2284-2303.
[2] WEINTRAUB D,AARSLAND D,CHAUDHURI K R,et al.The neuropsychiatry of Parkinson′s disease:advances and challenges[J].Lancet Neurol,2022,21(1):89-102.
[3] GALPER J,DEAN N J,PICKFORD R,et al.Lipid pathway dysfunction is prevalent in patients with Parkinson′s disease[J].Brain,2022,145(10):3472-3487.
[4] KUROUSKI D.Elucidating the role of lipids in the aggregation of amyloidogenic proteins[J].Acc Chem Res,2023,56(21):2898-2906.
[5] GARCA-SANZ P,M F G AERTS J,MORATALLA R.The role of cholesterol in α-synuclein and lewy body pathology in GBA1 Parkinson′s disease[J].Mov Disord,2021,36(5):1070-1085.
[6] SHAO Y,LI T,LIU Z,et al.Comprehensive metabolic profiling of Parkinson′s disease by liquid chromatography-mass spectrometry[J].Mol Neurodegener,2021〖KG-\*3〗,16(1):4.
[7] AHO V T E,HOUSER M C,PEREIRA P A B,et al.Relationships of gut microbiota,short-chain fatty acids,inflammation,and the gut barrier in Parkinson′s disease[J].Mol Neurodegener,2021,16(1):6.
[8] CHEN S J,CHEN C C,LIAO H Y,et al.Association of fecal and plasma levels of short-chain fatty acids with gut microbiota and clinical severity in patients with parkinson disease[J].Neurology,2022,98(8):e848-e858.
[9] SHIN C,LIM Y,LIM H,et al.Plasma short-chain fatty acids in patients with Parkinson′s disease[J].Mov Disord,2020,35(6):1021-1027.
[10] YOO D,LIM Y,SON Y,et al.Dietary intake and plasma levels of polyunsaturated fatty acids in early-stage Parkinson′s disease[J].Sci Rep,2021,11(1):12489.
[11] HERNANDO S,REQUEJO C,HERRAN E,et al.Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson′s disease:the role of glia and NRf2 regulation[J].Neurobiol Dis,2019,121:252-262.
[12] XICOY H,KLEMANN C J,WITTE W D,et al.Shared genetic etiology between Parkinson′s disease and blood levels of specific lipids[J].NPJ Parkinsons Dis,2021,7(1):23.
[13] FU X,WANG Y,HE X,et al.A systematic review and meta-ana-lysis of serum cholesterol and triglyceride levels in patients with Parkinson′s disease[J].Lipids Health Dis,2020,19(1):97.
[14] SINCLAIR E,TRIVEDI D K,SARKAR D,et al.Metabolomics of sebum reveals lipid dysregulation in Parkinson′s disease[J].Nat Commun,2021,12(1):1592.
[15] SNCHEZ CAMPOS S,ALZA N P,SALVADOR G A.Lipid metabolism alterations in the neuronal response to A53T α-synuclein and Fe-induced injury[J].Arch Biochem Biophys,2018,655:43-54.
[16] GUERREIRO P S,COELHO J E,SOUSA-LIMA I,et al.Mutant A53T α-synuclein improves rotarod performance before motor deficits and affects metabolic pathways[J].Neuromolecular Med,2017,19(1):113-121.
[17] TANDON P.Receptor-mediated release of inositolphosphates in brain slices[J].Methods Mol Med,1999,22:177-190.
[18] WOOD P L,TIPPIREDDY S,FERIANTE J,et al.Augmented frontal cortex diacylglycerol levels in Parkinson′s disease and Lewy body disease[J].PLoS One,2018,13(3):e0191815.
[19] BARBER C N,RABEN D M.Roles of DGKs in neurons:postsynaptic functions?[J].Adv Biol Regul,2020,75:100688.
[20] PANKRATZ N,WILK J B,LATOURELLE J C,et al.Genomewide association study for susceptibility genes contributing to familial Parkinson disease[J].Hum Genet,2009,124(6):593-605.
[21] POSOR Y,JANG W,HAUCKE V.Phosphoinositides as membrane organizers[J].Nat Rev Mol Cell Biol,2022,23(12):797-816.
[22] WANG B,TONTONOZ P.Phospholipid remodeling in physiology and disease[J].Annu Rev Physiol,2019,81:165-188.
[23] KANO K,AOKI J,HLA T.Lysophospholipid mediators in health and disease[J].Annu Rev Pathol,2022,17:459-483.
[24] HAMMOND G R V,BURKE J E.Novel roles of phosphoinositides in signaling,lipid transport,and disease[J].Curr Opin Cell Biol,2020,63:57-67.
[25] SIMONS K,TOOMRE D.Lipid rafts and signal transduction[J].Nat Rev Mol Cell Biol,2000,1(1):31-39.
[26] LPEZ DE FRUTOS L,ALMEIDA F,MURILLO-SAICH J,et al.Serum phospholipid profile changes in gaucher disease and Parkinson′s disease[J].Int J Mol Sci,2022,23(18):10387.
[27] REDDAN J M,WHITE D J,MACPHERSON H,et al.Glycerophospholipid supplementation as a potential intervention for supporting cerebral structure in older adults[J].Front Aging Neurosci,2018,10:49.
[28] THEODOROPOULOU S,GIALOURIS A G.Lipids and mental disorders:Evidence,uncertainties and perspectives[J].Psychiatriki,2019,30(2):129-141.
[29] FAROOQUI A A,HORROCKS L A.Excitotoxicity and neurological disorders:involvement of membrane phospholipids[J].Int Rev Neurobiol,1994,36:267-323.
[30] CHENG D,JENNER A M,SHUI G,et al.Lipid pathway alterations in Parkinson′s disease primary visual cortex[J].PLoS One,2011,6(2):e17299.
[31] LOBASSO S,TANZARELLA P,VERGARA D,et al.Lipid profiling of parkin-mutant human skin fibroblasts[J].J Cell Physiol,2017,232(12):3540-3551.
[32] WANG S,ZHANG S,LIOU L C,et al.Phosphatidylethanolamine deficiency disrupts α-synuclein homeostasis in yeast and worm models of Parkinson disease[J].Proc Natl Acad Sci U S A,2014,111(38):E3976-E3985.
[33] MU J,LAM S M,SHUI G.Emerging roles and therapeutic potentials of sphingolipids in pathophysiology:emphasis on fatty acyl heterogeneity[J].J Genet Genomics,2024,51(3):268-278.
[34] HANNUN Y A,OBEID L M.Sphingolipids and their metabolism in physiology and disease[J].Nat Rev Mol Cell Biol,2018,19(3):175-191.
[35] QUINVILLE B M,DESCHENES N M,RYCKMAN A E,et al.A comprehensive review:sphingolipid metabolism and implications of disruption in sphingolipid homeostasis[J].Int J Mol Sci,2021,22(11):5793.
[36] WANG L,LIN G,ZUO Z,et al.Neuronal activity induces glucosylceramide that is secreted via exosomes for lysosomal degradation in glia[J].Sci Adv,2022,8(28):eabn3326.
[37] PPIN ,JALINIER T,LEMIEUX G L,et al.Sphingosine-1-phosphate receptors modulators decrease signs of neuroinflammation and prevent Parkinson′s disease symptoms in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model[J].Front Pharmacol,2020,11:77.
[38] SIVASUBRAMANIAN M,KANAGARAJ N,DHEEN S T,et al.Sphingosine kinase 2 and sphingosine-1-phosphate promotes mitochondrial function in dopaminergic neurons of mouse model of Parkinson′s disease and in MPP+-treated MN9D cells in vitro[J].Neuroscience,2015,290:636-648.
[39] PYSZKO J,STROSZNAJDER J B.Sphingosine kinase 1 and sphingosine-1-phosphate in oxidative stress evoked by 1-methyl-4-phenylpyridinium (MPP+) in human dopaminergic neuronal cells[J].Mol Neurobiol,2014,50(1):38-48.
[40] ABBOTT S K,LI H,MU〖KG-\*3〗N〖DD(-\*3〗~OZ S S,et al.Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson′s disease[J].Mov Disord,2014,29(4):518-526.
[41] MIELKE M M,MAETZLER W,HAUGHEY N J,et al.Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson′s disease and associated with cognitive impairment:a pilot study[J].PLoS One,2013,8(9):e73094.
[42] YOON J,LEE C Y,V SCHAPIRA A H.Biochemical consequences of glucocerebrosidase 1 mutations in Parkinson′s disease[J].Neural Regen Res,2024,19(4):725-727.
[43] GALPER J,KIM W S,DZAMKO N.LRRK2 and lipid pathways:implications for Parkinson′s disease[J].Biomolecules,2022,12(11):1597.
[44] HU L,DONG M X,HUANG Y L,et al.Integrated metabolomics and proteomics analysis reveals plasma lipid metabolic disturbance in patients with Parkinson′s disease[J].Front Mol Neurosci,2020,13:80.
[45] HU G,ANTIKAINEN R,JOUSILAHTI P,et al.Total cholesterol and the risk of Parkinson disease[J].Neurology,2008,70(21):1972-1979.
[46] ASCHERIO A,SCHWARZSCHILD M A.The epidemiology of Parkinson′s disease:risk factors and prevention[J].Lancet Neurol,2016,15(12):1257-1272.
[47] YAN M,XIONG M,DAI L,et al.Cofilin 1 promotes the pathogenicity and transmission of pathological α-synuclein in mouse models of Parkinson′s disease[J].NPJ Parkinsons Dis,2022,8(1):1.
[48] CHEN R,GU X,WANG X.α-Synuclein in Parkinson′s disease and advances in detection[J].Clin Chim Acta,2022,529:76-86.
[49] SINGLETON A B,FARRER M,JOHNSON J,et al.Alpha-Synuclein locus triplication causes Parkinson′s disease[J].Science,2003,302(5646):841.
[50] BURR J,SHARMA M,SDHOF T C.Definition of a molecular pathway mediating α-synuclein neurotoxicity[J].J Neurosci,2015,35(13):5221-5232.
[51] BERNAL-CONDE L D,RAMOS-ACEVEDO R,REYES-HERNNDEZ M A,et al.Alpha-synuclein physiology and pathology:a perspective on cellular structures and organelles[J].Front Neurosci,2019,13:1399.
[52] BUSSELL R JR,ELIEZER D.A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins[J].J Mol Biol,2003,329(4):763-778.
[53] GALVAGNION C.The role of lipids interacting with α-synuclein in the pathogenesis of Parkinson′s disease[J].J Parkinsons Dis,2017,7(3):433-450.
[54] ADIBHATLA R M,HATCHER J F.Phospholipase a(2),reactive oxygen species,and lipid peroxidation in CNS pathologies[J].BMB Rep,2008,41(8):560-567.
[55] PUSPITA L,CHUNG S Y,SHIM J W.Oxidative stress and cellular pathologies in Parkinson′s disease[J].Mol Brain,2017,10(1):53.
[56] DING X S,GAO L,HAN Z,et al.Ferroptosis in Parkinson′s disease:molecular mechanisms and therapeutic potential[J].Ageing Res Rev,2023,91:102077.
[57] ANGELOVA P R,ESTERAS N,ABRAMOV A Y.Mitochondria and lipid peroxidation in the mechanism of neurodegeneration:finding ways for prevention[J].Med Res Rev,2021,41(2):770-784.
相似文献/References:
[1]马琪林,鲁丛霞,蔡琰,等.帕金森病患者血小板线粒体谷氨酸载体和复合物活性研究 [J].新乡医学院学报,2007,24(02):114.
[2]洪丽,李珂,闫晓海,等.瞬目反射与肛门括约肌肌电图对帕金森病患者病情分期判定的意义[J].新乡医学院学报,2012,29(12):936.
[3]朱丰霞,常海敏,段 瑛,等.人参皂苷 Rg1对帕金森病小鼠黑质中酪氨酸羟化酶及ephrinB2和磷酸化 c-Jun表达的影响[J].新乡医学院学报,2014,31(10):781.[doi:10.7683/xxyxyxb.2014.10.003]
[4]魏家彬,杨 帆,王淑秀.人参皂苷Rg1对1甲基4苯基1,2,3,6四氢吡啶诱导的帕金森病小鼠黑质酪氨酸蛋白激酶A4表达的影响[J].新乡医学院学报,2015,32(05):404.
[5]李 乐,黄志勇,贺文麟.血浆同型半胱氨酸、催乳素水平与帕金森病及帕金森病痴呆相关性分析[J].新乡医学院学报,2015,32(05):438.
[6]宋金辉,王普清,丁旭东,等.节律性视觉刺激对帕金森病患者运动功能及平衡能力的影响[J].新乡医学院学报,2014,31(12):1006.[doi:10.7683/xxyxyxb.2014.12.011]
[7]孙 冰,徐玉英.氧化苦参碱对帕金森小鼠中枢神经系统氧化应激的影响[J].新乡医学院学报,2020,37(6):509.[doi:10.7683/xxyxyxb.2020.06.002]
SUN Bing,XU Yuying.Effects of oxymatrine on oxidative stress of central nervous system in Parkinson mice[J].Journal of Xinxiang Medical University,2020,37(4):509.[doi:10.7683/xxyxyxb.2020.06.002]
[8]张静怡,邓永宁,张 萌,等.Sirt3基因过表达慢病毒载体的构建及其在人神经母细胞瘤SH-SY5Y细胞中的表达[J].新乡医学院学报,2021,38(1):006.[doi:10.7683/xxyxyxb.2021.01.002]
ZHANG Jingyi,DENG Yongning,ZHANG Meng,et al.Construction of lentiviral vector with Sirt3 gene overexpression and its expression in human neuroblastoma SH-SY5Y cells[J].Journal of Xinxiang Medical University,2021,38(4):006.[doi:10.7683/xxyxyxb.2021.01.002]
[9]汤丹丹,张 勋,符益纲,等.磁共振波谱在原发性帕金森病治疗效果评估中的应用价值[J].新乡医学院学报,2021,38(8):734.[doi:10.7683/xxyxyxb.2021.08.007]
TANG Dandan,ZHANG Xun,FU Yigang,et al.Value of magnetic resonance spectroscopy in evaluating the therapeutic effect of primary Parkinson′s disease[J].Journal of Xinxiang Medical University,2021,38(4):734.[doi:10.7683/xxyxyxb.2021.08.007]
[10]赵雪薇,陈珮琪,牛延翔,等.帕金森病的病因及发病机制研究进展[J].新乡医学院学报,2021,38(4):378.[doi:10.7683/xxyxyxb.2021.04.018]